Celularity Inc. Class A (CELU) Dividend History

Celularity Inc. Class A (CELU) is a biotechnology company that specializes in the development of cellular therapies derived from placental cells. Focused on regenerative medicine and immunotherapy, the company aims to create treatments for a variety of medical conditions, including cancer, infectious diseases, and degenerative disorders, leveraging the unique properties of placental stem cells.

170 Park Ave, Florham Park, NJ, 07932
Phone: (908) 768-2170
Website: https://www.celularity.com

Dividend History

Celularity Inc. Class A currently does not pay dividends

Company News

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Inc. (CELU) announced that it did not timely file its Q1 2025 financial report, leading to a Nasdaq non-compliance notice. The company has 60 days to submit a plan to regain compliance and may be granted an extension until November 2025 if the plan is accepted.

GlobeNewswire Inc.
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Celularity Inc. (CELU) received a Nasdaq delisting notice due to unpaid fees and a delinquent SEC filing. The company paid the outstanding fees and is working to file the 2024 Form 10-K.

GlobeNewswire Inc.
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Celularity welcomes CMS action to delay the effective date of a Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers from February 2025 to January 2026, ensuring continued access to these critical wound care products for Medicare patients.

GlobeNewswire Inc.
Amniotic Products Global Industry Report 2025: Growth in Regenerative Medicine Propels the Use of Amniotic Products in Tissue Repair and Healing

The global amniotic products market is expected to grow significantly, driven by advancements in regenerative medicine and the increasing use of amniotic products in tissue repair and healing. The Amniotic Membranes segment is projected to reach $1.2 billion by 2030, while the Amniotic Suspensions segment is also set to grow at a CAGR of 6.6%.

GlobeNewswire Inc.

Featured Companies: IART
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Celularity Inc. has regained compliance with Nasdaq listing rules after addressing a backlog of financial filings. The company has implemented process improvements, including engaging a new audit firm, to ensure timely and accurate reporting going forward.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 00:25:28 UTC